Clasp Therapeutics Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
41
- Latest Deal Type
-
Series A2
- Investors
-
16
Clasp Therapeutics General Information
Description
Developer of a precision oncology platform designed to support the development of targeted therapies for hard-to-treat cancers. The company's platform identifies tumor-specific neoantigens from oncogenic driver mutations and creates agents that selectively bind to HLA-presented peptides, enabling clinical-stage immuno-oncology firms to develop therapeutics that precisely target and destroy cancer cells across multiple tumor types.
Contact Information
Website
www.clasptx.comCorporate Office
- Alexandria Center at One Kendall Square
- Building 600/700, Suite 7-2027-202
- Cambridge, MA
- United States
Corporate Office
- Alexandria Center at One Kendall Square
- Building 600/700, Suite 7-2027-202
- Cambridge, MA
- United States
Clasp Therapeutics Timeline
Clasp Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series A2) | 15-Jan-2025 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series A) | 14-Dec-2023 | Completed | Clinical Trials - Phase 1 | |||
| 1. Accelerator/Incubator | Completed | Startup |
Clasp Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A2 | ||||||||
| Series A-1 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Clasp Therapeutics Comparisons
Industry
Financing
Details
Clasp Therapeutics Competitors (81)
One of Clasp Therapeutics’s 81 competitors is etherna, a Formerly VC-backed company based in Niel, Belgium.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| etherna | Formerly VC-backed | Niel, Belgium | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| EvolveImmune Therapeutics | Venture Capital-Backed | Branford, CT | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Carisma Therapeutics | Formerly VC-backed | Philadelphia, PA |
Clasp Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Clasp Therapeutics Patents
Clasp Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024380488-A1 | Modified mana-tces targeting tumor antigens and engaging t cell receptors, and methods of using thereof | Pending | 13-Nov-2023 | ||
| EP-4808968-A1 | Modified mana-tces targeting tumor antigens and engaging t cell receptors, and methods of using thereof | Pending | 13-Nov-2023 | ||
| WO-2025106598-A1 | Modified mana-tces targeting tumor antigens and engaging t cell receptors, and methods of using thereof | Inactive | 13-Nov-2023 | C07K16/2833 |
Clasp Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Clasp Therapeutics Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bow River Capital | PE/Buyout | Minority | ||
| ACS BrightEdge | Corporate Venture Capital | Minority | ||
| Alexandria Venture Investments | Venture Capital | Minority | ||
| Blackbird BioVentures | Venture Capital | Minority | ||
| Catalio Capital Management | Venture Capital | Minority |
Clasp Therapeutics FAQs
-
When was Clasp Therapeutics founded?
Clasp Therapeutics was founded in 2020.
-
Where is Clasp Therapeutics headquartered?
Clasp Therapeutics is headquartered in Cambridge, MA.
-
What is the size of Clasp Therapeutics?
Clasp Therapeutics has 41 total employees.
-
What industry is Clasp Therapeutics in?
Clasp Therapeutics’s primary industry is Biotechnology.
-
Is Clasp Therapeutics a private or public company?
Clasp Therapeutics is a Private company.
-
What is Clasp Therapeutics’s current revenue?
The current revenue for Clasp Therapeutics is .
-
How much funding has Clasp Therapeutics raised over time?
Clasp Therapeutics has raised $150M.
-
Who are Clasp Therapeutics’s investors?
Bow River Capital, ACS BrightEdge, Alexandria Venture Investments, Blackbird BioVentures, and Catalio Capital Management are 5 of 16 investors who have invested in Clasp Therapeutics.
-
Who are Clasp Therapeutics’s competitors?
etherna, CytomX Therapeutics, EvolveImmune Therapeutics, Adaptimmune Therapeutics, and Carisma Therapeutics are some of the 81 competitors of Clasp Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
